TrialThe Lancet. Oncology2011

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Robert L Coleman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.